PLRX – pliant therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Pliant Therapeutics to Participate in Upcoming Investor Events
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Form SC 13G PLIANT THERAPEUTICS, Filed by: Redmile Group, LLC
Form SC 13G/A PLIANT THERAPEUTICS, Filed by: Blue Owl Capital Holdings LP
Form SC 13G/A PLIANT THERAPEUTICS, Filed by: First Light Asset Management, LLC
Form SC 13G/A PLIANT THERAPEUTICS, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Form SC 13G/A PLIANT THERAPEUTICS, Filed by: Laurion Capital Management LP
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.